Effect of obstructive sleep apnea on response to cognitive behavior therapy for depression after an acute myocardial infarction

Kenneth E. Freedland a,⁎, Robert M. Carney a, Junichiro Hayano b, Brian C. Steinmeyer a, Rebecca L. Reese a, Annelieke M. Roest c

a Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
b Department of Medical Education (J.H.), Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
c Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Abstract

Objective: To determine whether obstructive sleep apnea (OSA) interferes with cognitive behavior therapy (CBT) for depression in patients with coronary heart disease.

Methods: Patients who were depressed within 28 days after an acute myocardial infarction (MI) were enrolled in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) trial; 289 (12%) of the 2481 participants in ENRICHD met the criteria for inclusion in this ancillary study.

Results: A validated ambulatory ECG algorithm was used to detect OSA. Of the 289 participants, 64 (22%) met the criteria for OSA. CBT was efficacious relative to usual care (UC) for depression (p = .004). OSA had no effect on 6-month Beck Depression Inventory (BDI) scores (p = .11), and there was no interaction between OSA and treatment (p = .42). However, the adjusted mean (s.e.) 6-month BDI scores among patients without OSA were 12.2 (0.8) vs. 9.0 (0.8) in the UC and CBT groups (Cohen’s d = .40); among those with OSA, they were 9.5 (1.4) and 8.1 (1.5) in the UC and CBT groups (d = .17). There were no significant OSA x Treatment interactions in the major depression (n = 131) or minor depression (n = 158) subgroups, but in those with major depression, there was a larger treatment effect in those without (d = .44) than with (d = .09) OSA. In those with minor depression, the treatment effects were d = .37 and d = .25 for the non-OSA and OSA subgroups.

Conclusion: CBT is efficacious for depression after an acute myocardial infarction in patients without obstructive sleep apnea, but it may be less efficacious for post-MI patients with OSA.

© 2012 Elsevier Inc. All rights reserved.

Introduction

Depression is a treatable disorder, but at least 30% of patients do not respond to standard therapies [1]. For example, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial tested a stepped treatment algorithm that incorporated patient preference. About 33% of 3671 patients remitted during initial treatment with citalopram. Subsequent treatments for patients who did not remit on citalopram included up to 3 more steps involving switching to, or augmentation with, other antidepressants and/or cognitive behavior therapy (CBT). Of the 3671 patients who were initially treated with citalopram, 1872 remitted at the first, second, third, or fourth step, for a cumulative remission rate of 51% [2,3]. Thus, even with aggressive, stepped treatment protocol, almost half of the patients did not remit. Furthermore, relapse rates increased along with the number of steps [4].

Early response to treatment has emerged as a relatively strong predictor of subsequent remission of depression [5-7]. Efforts to identify pretreatment patient characteristics that can accurately predict response to treatment for depression have been less successful [5]. Pretreatment predictors of poor response to treatment include a history of attempted suicide [8]; recent, severely stressful life events, particularly involving job loss or financial distress [9]; high levels of anxiety [8]; and somatic symptoms [10] in general and painful somatic symptoms in particular [11]. Candidate gene and genome-wide association studies have begun to identify single nucleotide polymorphisms that may be related to treatment responsiveness [12-15]. Other promising biomarkers have been identified as well, including ones...
derived from proteomic, metabolomic, and brain imaging studies [16]. Nevertheless, our ability to identify treatment-resistant cases of depression prior to treatment remains quite limited.

Treatment-resistant depression may have particularly serious implications for patients with coronary heart disease (CHD). Recent findings from several clinical trials have shown that patients who do not respond to standard treatments for depression are at high risk for mortality after acute coronary syndrome [17].

The prevalence of comorbid major depression in CHD is approximately 15% to 20%, and scores in the “depressed” range on self-report questionnaires are even more common [18]. Many patients with CHD and comorbid depression also have obstructive sleep apnea (OSA) [19]. Patients with OSA have repetitive episodes of complete (apnea) or partial (hypopnea) obstruction of the upper airway during sleep. During these episodes, there are efforts to breathe but inspiration is temporarily blocked. Many patients with obstructive OSA also have central apneic episodes in which breathing stops temporarily but without any airway blockage or respiratory effort. Both kinds of episodes can cause harmful reductions in the level of oxygen in the blood [20]. The prevalence of OSA is increasing along with the epidemic of obesity in the United States [21]. Sleep apnea is associated with a variety of adverse cardiovascular and metabolic effects [22,23]. It is also associated with depression [24], cognitive impairment [25], and structural changes in the brain [24,26]. Nevertheless, OSA is still markedly underdiagnosed and undertreated, even among cardiac patients at high risk of OSA-related mortality [19,27].

We recently reported that untreated OSA predicts a poor response to sertraline in patients with stable CHD and comorbid major depressive disorder (MDD) [28]. This was a secondary analysis of a randomized, double blind, placebo-controlled trial of omega-3 free fatty acid augmentation of sertraline, the primary results of which were reported elsewhere [29]. A previously validated algorithm [30] for detecting OSA was applied to 105 of the trial participants’ baseline electrocardiographic (ECG) data; 30 (29%) were classified as having moderate to severe OSA, with an algorithm-derived AHI ≥ 15. The mean (standard deviation) scores on the Beck Depression Inventory (BDI-II) [31] after treatment with sertraline were 19.0 (11.0) among patients with OSA and 13.0 (9.2) in those without OSA (p = 0.01). This difference remained significant after adjustment for the baseline severity of depression, treatment group (omega-3 vs. placebo), body mass index (BMI), and inflammatory markers.

These findings suggest that untreated OSA can interfere with antidepressant therapy, but their generalizability to other forms of treatment for depression is unknown. Because OSA is often associated with daytime sleepiness, fatigue, and poor concentration, especially if left untreated [32], it might be especially problematic for nonpharmacological interventions such as CBT that depend upon the participant’s attentive engagement in therapy.

The present study investigated this question in a secondary analysis of data from the Enhancing Recovery in Coronary Heart Disease (ENRICHD) trial. In ENRICHD, patients with a recent history of acute myocardial infarction (MI) were randomly assigned to CBT or to usual care (UC) for depression. Data on OSA were obtained from a subset of ENRICHD participants. We used these data to test the hypothesis that OSA moderates the effect of CBT on depression in patients with a recent MI, and specifically that patients with OSA do not respond as well to CBT for depression as do patients without OSA.

Methods

Eligibility criteria

The methods, treatment protocol, and primary findings of the ENRICHD trial have been reported elsewhere [33-35]. Briefly, consenting patients were assessed for depression and low perceived social support within 28 days after an acute MI. Those who met the trial’s eligibility criteria were randomly assigned to 6 months of CBT or to UC for depression. In some cases, the cognitive–behavioral intervention was augmented with an antidepressant. Antidepressant therapy was offered only to patients who were severely depressed at enrollment or who had an inadequate response to the first 5 weeks of CBT. The primary analyses showed that although the intervention had significant effects on depression and social support, it had no impact on reinfarction-free survival [33]. To be included in this ancillary study, participants had to meet the ENRICHD criteria for a major or minor depressive episode at baseline, have a Beck Depression Inventory (BDI) [36] score of 10 or greater, and to have provided usable baseline ECG data for an ENRICHD Holter monitoring substudy [37]. The ENRICHD trial and the ancillary ECG study were approved by the institutional review board at each participating site and were carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Procedures

OSA was identified from cyclic variation of heart rate (CVHR) patterns detected in 24-hour Holter ECG recordings that were obtained within 28 days (median, 13 days) after the index MI. The ECGs were scanned on an XXP Laser scanner (Marquette Electronics). The labeled beat files were exported to a computer workstation on which CVHR was detected by an autocorrelated wave detection with adaptive threshold (ACAT) algorithm. The ACAT algorithm is a time-domain method for detecting CVHR from interbeat interval data. Details of this method have been reported elsewhere [38]. Briefly, the algorithm detects transient tachycardia as CVHR when it meets the following criteria: 1) width from 10 to 120 s, 2) depth-to-width ratio >0.7 ms/s, 3) depth >40% of the 90% CI of local interbeat interval variations, 4) cycle length (interdig interval) from 25 to 120 s, 5) similar waveforms for 5 consecutive dips (morphological correlation coefficients >0.4) and 6) three equivalent consecutive cycle lengths with a tolerance of 22% against the mean cycle length. In a validation study of 862 patients referred to a sleep medicine center for a diagnostic evaluation, the CVHR index correlated very highly (r = 0.84) with the apnea-hypopnea index (AHI) derived from polysomnography. The CVHR index cutoff of ≥ 15 per hour approximates an AHI of ≥ 15, the standard polysomnographic cutoff for identifying patients with moderate-to-severe OSA [39]. At this cutpoint, the CVHR index has 83% sensitivity, 88% specificity, and 91% accuracy vis-à-vis the AHI cutoff [38].

Holter diary data and diurnal heart rate patterns were used to establish each participant’s sleep period. The average number of CVHRs per hour during the sleep period was calculated by a technician who was blinded to patient characteristics and CVHR analysis results. Participants who averaged > 15 CVHRs per hour were classified as having OSA. The ENRICHD medical history data collection forms did not include any questions about OSA, so it is not possible to determine whether any of the participants had been evaluated at a sleep medicine center, diagnosed with OSA, or treated with continuous positive airway pressure (CPAP). However, if other research on cardiac patients [19] generalizes to the ENRICHD sample, it is likely that very few of the participants had ever been clinically evaluated or treated for OSA. In middle-aged adults, about 93% of moderate to severe cases of OSAHS in women and 82% in men escape clinical diagnosis [27].

The Beck Depression Inventory [36] is a 21-item measure of the severity of self-reported depression symptoms. Each symptom is rated on a 0–3 scale, and the total scores range from 0 to 63. A score of 10 or higher is the standard cutoff for clinically significant depression. The BDI was administered at baseline and repeated 6 months later to assess depression outcomes. The Depression Interview and Structured Hamilton (DSH) [40] was used to classify participants as meeting the study’s criteria for a major or minor depressive episode at baseline.
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات